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Abstract 
Uveal melanoma is the most common primary intraocular tumor in adults, and it has a strong potential to metasta-
size. Traditionally, clinicopathological features of these tumors were used to provide a limited prediction of the meta-
static risk. However, early genetic studies using karyotype analysis, fluorescence in situ hybridization, and comparative 
genetic hybridization of posterior uveal melanoma samples identified multiple chromosomal abnormalities associ-
ated with a higher risk of fatal metastasis. This correlation between specific genetic abnormalities in uveal melanoma 
and a patient’s risk for development of metastasis has recently been widely studied, and the development of new 
prognostic tests has allowed clinicians to predict this metastatic risk with increased accuracy. Such novel tests include 
gene expression profiling, which analyzes the RNA expression patterns of tumor cells, and multiplex ligation-depend-
ent probe amplification, which detects deletions or and amplifications of DNA in tumor cells. This review discusses the 
current status of prognostic testing techniques available to clinicians and patients for posterior uveal melanomas.
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Background
Posterior uveal melanoma (PUM) is the most common 
primary tumor of the eye, and it carries a high risk for 
metastasis, primarily to the liver. Approximately 50  % 
of patients with PUM will develop fatal metastases, and 
many patients will die within a year of their metastatic 
diagnosis [1]. Often, by the time metastatic disease is 
detectable on imaging studies, the tumor burden is sub-
stantial and therapeutic options are limited [2]. Given 
the potentially aggressive nature of these tumors, 97  % 
of patients reportedly desire prognostic information in 
order to make decisions about management and surveil-
lance testing for metastasis from their uveal melanoma 
[3]. Traditionally, demographic and clinicopathologic 
features of these tumors have been used to determine the 
metastatic risk of a PUM. Such features as older patient 
age, larger tumor basal diameter, invasion of the sclera, 
ciliary body involvement, and epithelioid cell type have 
been associated with worse patient prognosis and a 
higher incidence of metastatic disease [4]. Although these 
identified risk factors are still widely used, their accuracy 
to predict metastatic potential has been shown to be lim-
ited. With the rapid development of new molecular tech-
niques that allow for examination of the genetic make-up 
of tumor cells, more accurate prognostic information has 
become available to clinicians and patients. This prog-
nostic information allows for personalized clinical deci-
sion-making and hopefully more targeted therapeutic 
options. Novel techniques such as gene expression profil-
ing (GEP) and multiplex ligation-dependent probe ampli-
fication (MLPA) have improved upon the initial methods 
for genetic testing like karyotype analysis, fluorescence 
in  situ hybridization (FISH), and comparative genomic 
hybridization (CGH). Although some of the methods 
described herein are not easily accessible throughout the 
world, it is important that physicians are up to date with 
the latest advances in the prognostication of PUM. In this 
manuscript, the authors review the recent developments 
and current status of prognostic testing of patients with 
PUM, what these tests analyze, and how their results can 
be applied in clinical practice (Fig. 1).
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Karyotype analysis
In the early 1990s, initial genetic studies of PUM exam-
ined the implications of a gain or loss of specific chro-
mosomes in these tumors. Through karyotype analysis, 
Prescher et al. discovered that monosomy 3 and increased 
copies of chromosome 8q were commonly found in PUM 
samples [5]. Further studies by these authors demon-
strated an increased potential for metastatic disease in 
patients with such chromosomal abnormalities. Accord-
ing to the authors, patients who retained both copies of 
chromosome 3 exhibited no metastatic disease within 
the median follow-up time of 3.4  years, whereas 57  % 
of patients with monosomy 3 developed metastases [6]. 
Given its prognostic importance, monosomy 3 has sub-
sequently remained the focus of many genetic studies [7]. 
In addition to monosomy 3, a gain in chromosome 8q has 
also been linked with poor survival prognosis [8]. Karyo-
type analysis has been proven accurate for tumors with 
obvious gain or loss of entire chromosomes, but it failed 
to detect minor genetic changes. Further, the 10-year 
reported mortality of patients with disomy 3 was 30  % 
and those with monosomy 3 loss was 100 %; patients with 
Fig. 1 Posterior uveal melanoma prognostic test flow-chart. Because the current prognostic tests rely on either DNA or RNA extraction from tumor 
specimens. Tumor tissue procurement should be done ideally prior to any form of local destructive treatment that may alter the DNA and/or RNA of 
the tumor cells (including radiation). Tissue can be obtained from either an enucleation specimen that has been formalin-fixed and paraffin-embed-
ded (FFPE) or a fine needle aspiration biopsy (FNAB) of the tumor prior to conservative treatment or immediately after enucleation. FFPE scrapings 
from an enucleation specimen can be sent for DNA extraction and can allow for further analysis of the tumor through karyotyping, FISH (fluo-
rescence in situ hybridization), CGH (comparative enomic hybridization), MLPA (multiplex ligation-dependent probe amplification), or GEP (gene 
expression profiling). Through FNAB, small quantity of fresh tumor cells is extracted from the tumor. These cells can be sent for cytology, GEP, or 
MLPA. GEP relies primarily on RNA extraction from these cells but it can also be performed using DNA. MLPA relies solely upon DNA extraction. GEP 
stratifies tumors into Class 1A, Class 1B, or Class 2 based 12 discriminating genes and 3 control genes. MLPA yields a complex report describing risk 
stratification of the test that includes the genetic information yielded, clinical features of the tumor, and patient demographics. Estimated 10-year 
metastasis-free survival is listed based on publications on karyotype analysis [9], FISH [12], MLPA [13]. Estimated 5-year metastasis-free survival based 
on GEP classification is also listed [7]
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no chromosome 8q amplification was 40  %, and those 
with chromosome 8q amplification was 80  % [9]. How-
ever, karyotype analysis can additionally provide false 
negative results in cases of isodisomy 3 found in some 
PUM. A study by White et al. identified uveal melanomas 
that had developed acquired homozygosity of chromo-
some 3, otherwise known as isodisomy 3. In short, during 
their progression, such tumors lose one copy of chromo-
some 3, and start duplicating their remaining third chro-
mosome. On karyotype analysis, the duplicated genetic 
material remains undetected even though the tumors 
demonstrate functional monosomy [10].
Comparative genomic hybridization
Comparative genomic hybridization (CGH) is a tech-
nique that helps to identify a gain or loss of chromosomal 
material within tumor DNA. Normal DNA and tumor 
DNA are labeled with different fluorescent probes and 
subsequently hybridized. An increase or decrease in the 
color ratio of the fluorescent probes identifies areas of 
abnormal chromosomal material. While it has been used 
to study the cytogenetics of PUM, CGH fails to detect 
partial deletions or smaller defects in the tumor DNA 
[11].
Fluorescence in situ hybridization
Fluorescence in  situ hybridization (FISH) is method for 
detecting the gain or loss of chromosomal material that 
can be used in several different tissue samples including 
PUM. FISH uses labeled fluorescent probes that match 
specific DNA target sequences. Through FISH, changes 
in the DNA copy number of these sequences can be 
determined in both fresh tissue samples and paraffin-
embedded tumor specimens. Analysis of tumor samples 
using FISH has identified monsomy 3 and amplification 
of 8q in PUM to be associated with poor disease-free 
10-year survival in a study by van den Bosh et  al. [12]. 
Although FISH has been shown to be accurate in detect-
ing gain or loss of larger DNA sequences similar to CGH, 
it often misses minor chromosomal defects or aberra-
tions. Thus, it has limited utility in making a precise clini-
cal prediction in patients who have no detectable loss or 
gain of chromosomal material [13].
Gene expression profiling
As a relatively novel technique, gene expression pro-
filing (GEP) can be used for rapid detection of the up-
regulation or down-regulation of particular genes of 
interest in minute tissue samples. The technique involves 
the isolation of RNA from a tissue sample, followed by 
conversion to cDNA that is subsequently hybridized 
to genechips, and microarray analysis is performed. 
Through GEP assay of untreated PUM tissue samples, 
Harbour and associates demonstrated two distinct prog-
nostic classes that can be used to predict metastatic risk 
and strongly correlates with patient survival [14]. The 
authors initially identified 62 genes that showed distinct 
aberrant expression patterns. When combined with the 
clinical outcome of patients, the up-regulation or down-
regulation of specific gene clusters identified by the 
GEP assay allowed for this new stratification scheme. 
Patients with class 1 tumor gene expression profiles have 
low-grade tumors with a decreased risk of metastatic 
spread. On the other hand, patients with Class 2 tumor 
gene expression profiles have high-grade tumors with 
an increased tendency to metastasize [14]. When com-
pared to the presence of monosomy 3 and the clinical 
and pathologic tumor features, GEP demonstrated supe-
rior accuracy at predicting the risk of metastatic disease 
in patients with PUM [4]. While both CGH and FISH 
provide a snapshot in time of the genetic make-up of the 
tumor cells, because GEP is an RNA based assay, it pre-
dicts how the tumor cells are likely to behave as far as 
metastatic spread.
Following the initial study of GEP in PUM samples, 
Harbour and associates developed a 15-gene PCR based 
assay that enabled discrimination of Class 1 and Class 2 
tumors. The assay examines the expression patterns of 
12 class discriminating genes identified by the previous 
analysis and 3 control genes shown to be unchanged in 
uveal melanomas [2]. Although GEP can be performed in 
paraffin fixed tissue, tumor cell procurement for this test 
is mainly done by fine needle aspiration biopsy (FNAB) 
at the time of plaque implantation or immediately after 
enucleation of the eye containing the tumor. The fresh 
tumor aspirate obtained is flushed in a buffer solution 
and then frozen until the time of the test. The assay was 
then tested in a multicenter prospective clinical trial in 
the Collaborative Ocular Oncology Group Report Num-
ber 1, where it correctly classified tumors in 97.2  % of 
cases [15]. Now commercially available as DecisionDx-
UM® (Castle Biosciences, Tucson, AZ), the assay can be 
used routinely to provide patients with prognostic infor-
mation about their tumors [16]. Since the development 
of the assay, Class 1 tumors have been further subdivided 
in Class 1A and Class 1B. Class 1A tumors have a 2  % 
5-year metastatic risk while Class 1B tumors have a 21 % 
5-year metastatic risk. By contrast, Class 2 tumors have a 
72 % 5-year metastatic risk. This prognostic information 
has had significant implications for the ongoing clinical 
monitoring of patients with uveal melanomas [7]. A study 
by Correa et al. determined that the GEP assay provides 
genomic information even in very minute specimens 
using fine needle aspiration biopsy aspirates. According 
to the study, only 0.6 % of all 159 cases had a failed result 
[17].
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Interestingly, in very small tumors, heterogeneous 
genetic make-up could potentially limit the accuracy 
of this test (and likely any other test used in samples 
obtained by needle aspirates) in a small number of 
patients. In a study by Augsburger et al. tumor sampling 
from different sites within the same tumor demonstrated 
discordance of GEP classification in 11.3 % of cases [18]. 
However, the authors noted a correlation between the 
thickness of the tumor and GEP discordance between 
biopsies. The study showed discordant GEP results were 
found in 23.8  % of tumors that were less than 3.5  mm 
thick, 16.7 % of tumors between 3.5 and 7 mm thick and 
only 4.3 % of tumors thicker than 7 mm. The authors con-
cluded that performing a GEP on a biopsy sample from 
a single tumor site carries a risk of prognostic misclassi-
fication that is significant in smaller tumors. This study 
recommend taking this information into account when 
advising patients with smaller tumors about their prog-
nosis [18]. Meanwhile, the authors are working on a pro-
spective study looking at GEP discordance in small PUM.
Multiplex ligation‑dependent probe amplification
Schouten et  al. described a method termed multiplex 
ligation-dependent probe amplification (MLPA) that can 
be used for detecting the relative quantities of as many 
as 40 different DNA sequences [19]. MLPA analyzes the 
gain and loss of chromosomal material. Through the 
reaction, denatured genomic DNA is mixed with probes 
for the specific target genes of interest. The probes each 
consist of two oligonucleotides that will hybridize to 
adjacent sites on the target DNA sequences. One of these 
oligonucleotides contains a stuffer sequence of unique 
length. Following hybridization, the probes are ligated 
and amplified by PCR. The individual stuffer sequences 
give each probe a unique length that enables effective 
separation via electrophoresis. The separated PCR prod-
ucts can be quantified and the amount extrapolated to 
determine the relative expression of the gene products. 
MLPA is sensitive and sequence specific in detecting 
changes in DNA copy numbers and detects deletions and 
amplifications of single exons [19]. MLPA can be per-
formed on fresh frozen and formalin-fixed and paraffin-
embedded tissue samples, although fresh frozen samples 
are preferable [20].
The application of MLPA to PUM tissue samples was 
subsequently described by Damato et  al. Their initial 
study analyzed uveal melanoma tissue samples from 73 
patients. MLPA detected chromosomal abnormalities 
that correlated with metastatic death, most importantly 
loss of chromosome 3 and gain of chromosomal material 
on 8q [21]. In a larger study from the same group, chro-
mosomes were considered abnormal if any of the loci 
examined showed either borderline or definite gain or 
loss [13]. The results showed that chromosome 1p loss, 
chromosome 3 loss, and chromosome 8q gain correlated 
with increased mortality whereas chromosome 6p gain 
correlated with improved survival. The mortality rate 
was 0 % in 133 patients without any evident chromosome 
3 loss and 71 % in patients with both monosomy 3 and 
8q gain with a median follow up time of 1.89 years. The 
MLPA results additionally correlated with the clinico-
pathological features of the tumors. Through this study, 
MLPA provided relevant prognostic information related 
to chromosomal aberrations to patients with uveal mela-
nomas. While the MLPA results of this study provided 
accurate prognoses, it does not offer similar stratification 
of cases as GEP and prognostication requires detailed 
interpretation by the clinician ordering the test and it can 
still be improved by clinicopathologic correlation [13]. 
MLPA is now commercially available through Impact 
Genetics, Toronto, Canada.
Based upon previous evidence of genetic heterogene-
ity, Dopierala et  al. examined a larger number of cases 
to determine the percentage of intratumor heterogeneity 
seen in formalin-fixed paraffin-embedded PUM through 
MLPA. Their results indicated that 75  % of the tumors 
showed heterogeneity in one or more loci on chromo-
somes 1, 3, 6, or 8. The authors of the study conclude that 
an MLPA result from a single random formalin-fixed and 
paraffin-embedded sample from a PUM may not provide 
an accurate representation of the tumor’s genetics. In 
contrast to studies using GEP, MLPA identified a higher 
percentage of tumors with a heterogeneous genetic 
make-up in this study [22].
Mutational profiling
Although not useful in prognostication of patients, detec-
tion of specific mutations in uveal melanomas may lead 
to improved therapeutic options in the future. Through 
a search for mutations in the oncogenic pathway involv-
ing RAF, MEK, and ERK, Onken et  al. first identified a 
mutation in the stimulatory alpha(q) G protein subunit 
known as GNAQ in approximately 50 % of PUM samples. 
A mutation in GNAQ was detected in PUM samples at 
all of the stages of malignant progression, indicating that 
such a mutation may play a role in the initial develop-
ment of the tumor [23]. Van Raamsdonk et  al. discov-
ered that mutations in the protein GNA11, a paralogue 
of GNAQ, were found in 32 % of PUM samples and 57 % 
of PUM metastases. Furthermore, the authors found that 
mutations in GNA11 were sufficient to induce metasta-
ses in a mouse model. Mutations in GNAQ and GNA11 
affect a critical oncogenic signaling cascade that affects 
the metastatic potential of tumors [24]. Ewens et al. dem-
onstrated that identification of specific mutations may 
have prognostic significance when combined with the 
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chromosome 3 status of the tumor. In their study of 63 
cases of PUM, GNA11 and BAP1 mutations were asso-
ciated with a greater metastatic risk while a mutation 
in EIF1AX was associated with a lower metastatic risk 
within the 48 months of follow up [25]. These mutations 
may provide targets for therapeutics. Specific inhibitors, 
such as the MEK inhibitor selumetinib, can be designed 
to interrupt the pathways of these oncogenic proteins 
and may have important clinical implications [7].
Discussion
While relatively new, prognostic testing is becoming an 
important component in the metastatic risk stratification 
of patients with PUM. Understanding the information 
obtained by each test and its application is fast becoming 
an important part of ocular oncology clinical practice. 
Table 1 briefly highlights features of different prognostic 
tests currently used for uveal melanoma. Although sensi-
tive in detecting large chromosomal abnormalities such 
as monosomy 3, karyotype analysis, FISH, and CGH have 
largely been replaced by more recently developed prog-
nostic tests like GEP and MLPA. GEP analyzes the RNA 
expression patterns of the tumor cells and provides a pre-
cise classification for metastatic risk. Whilst it carries a 
modest risk of mis-classification due to possible genetic 
heterogeneity in smaller tumors, it is the most robust 
independent predictor of metastatic risk for patients with 
uveal melanoma. MLPA detects deletions and amplifi-
cations of DNA in tumor cells, and it offers information 
about the common chromosomal abnormalities associ-
ated with metastatic risk in PUM. As MLPA identifies 
high rates of genetic heterogeneity in PUM, particularly 
in formalin-fixed and paraffin-embedded samples, cor-
relation with the clinical and pathologic features of the 
tumors seems essential in providing patients with accu-
rate information and makes test interpretation more 
complex and prognostication less clear. Further, the 
reported failure rate of MLPA is higher than GEP.
In short, there is significant discussion about which 
one of these is the best prognostic test for uveal mela-
noma? In the authors’ opinion, the best prognostic test 
is one with the highest negative predictive value and 
fewer prognostic subgroups. Based on this premise, 
GEP should be the preferred prognostic test because 
it has the aforementioned features and is the only one 
validated prospectively in a multi-center clinical trial 
[15]. Whenever GEP testing is not available; FISH and 
MLPA provide comparable chromosomal information 
[26]. Because the accuracy of FISH and MLPA is not as 
high as GEP it is recommended that additional clinical 
information including patient demographic informa-
tion, tumor features, histo and/or cytopathology be 
considered to improve their prognostic precision [27]. 
Centers where neither of these tests is available can 
resort to cytology for prognosis [28] but should also 
add clinical information to improve their prognostic 
accuracy [29].
Conclusions
Although the therapeutic options currently available for 
metastatic PUM are limited, patients still desire accu-
rate prognostic information about their tumors at the 
time of diagnosis in order to plan their management. In 
the future, more standardized metastatic surveillance 
for those patients found to have aggressive tumors might 
allow for earlier detection of metastatic disease and 
improved clinical management. While these prognos-
tic tests have not yet led to new therapies for PUM, they 
provide a critical step in the direction towards identify-
ing specific therapeutic modalities that target the genetic 
abnormalities of these tumors.
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Table 1 Comparison of laboratory tests currently available for prognosis of posterior uveal melanomas
FISH fluorescence in situ hybridization; CGH comparative genomic hybridization; MLPA multiplex ligation-dependent probe amplification; GEP gene expression 
profiling; FFPE formalin fixed paraffin embedded; NR not reported
Karyotype FISH CGH GEP MLPA
Type of analyses Chromosomes DNA DNA RNA or DNA DNA
Monosomy 3 detection Yes Yes Yes No Yes
Tissue used FFPE FFPE FFPE FFPE or fresh FFPE or fresh
Reported tumor heterogeneity NR NR NR 11.3 % 75 %
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